Recurrent Salivary Gland Carcinoma Active Not Recruiting Phase 1 / 2 Trials for Vorinostat (DB02546)
| Indication | Status | Phase |
|---|---|---|
| DBCOND0037143 (Recurrent Salivary Gland Carcinoma) | Active Not Recruiting | 1 / 2 |
| clinicaltrials.gov Identifier | Title | Purpose | Drugs |
|---|---|---|---|
| NCT02538510 | Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery | Treatment |